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Duchenne muscular dystrophy (DMD) patients and mdx mace are characterized by the absence of dystrophin. a membrane cytoskeletal protem. 
Dystrophin ts assoctated with a large ohgomeric complex of sarcolemmal glycoproteins. mcludmg dystroglycan which provtdes a hnkage to the 
extarcellular matrix component, laminin. The finding that all of the dystrophm-assoctated proteins (DAPs) are drastically reduced in DMD and 
mdx skeletal muscle supports the prtmary functton of dystrophin as an anchor of the sarcolemmal glycoprotein complex to the subsarcolemmal 
cytoskeleton. These findings indicate that the efficacy of dystrophm gene therapy will depend not only on replacmg dystrophin but also on restormg 
all of the DAPs m the sarcolemma Here we have investigated the status of the DAPs in the skeletal muscle of mdx mice transgemc for the dystrophm 
gene. Our results demonstrate that transfer of dystrophin gene restores all of the DAPs together with dystrophm, suggestmg that dystrophm gene 
therapy should be effecttve in restoring the entire dystrophtnglycoprotein complex. 
Duchenne muscular dystrophy; Mdx mouse; Transgenic mouse; Dystrophm: Dystrophu-glycoprotem complex. Dystrophm-assoctated protein 
1. INTRODUCTION 
The absence of dystrophin, a membrane cytoskeletal 
protein. is the primary cause of Duchenne muscular 
dystrophy (DMD) and mdx mice [1,2]. Dystrophin is 
associated with a large oligomeric complex of sarcolem- 
ma1 glycoproteins [3-61, including dystroglycan which 
binds laminin, a major protein component of the ex- 
tracellular matrix [7]. Although dystrophin constitutes 
only 0.002% of the total skeletal muscle [I], it consti- 
tutes 2% of total sarcolemmal proteins and 5% of sar- 
colemmal cytoskeletal proteins [8.9]. Dystrophin also 
interacts with F-actin [ 10-121. Thses findings indicate 
that the dystrophin-glycoprotein complex (DGC) is a 
major trans-sarcolemmal structure which provides a 
linkage between the subsarcolemmal cytoskeleton and 
the extracellular matrix. 
In DMD patients and mdx mice, the absence of 
dystrophin leads to a drastic reduction in all of the 
dystrophin-associated proteins (DAPs) in the sar- 
colemma, thus causing the disruption of the linkage 
between the subsarcolemmal cytoskeleton and the ex- 
tracellular matrix [4,7,13,14]. This is presumed to cause 
the sarcolemmal instability, which, in turn, may render 
muscle fibers susceptible to necrosis [ 13,141. The signif- 
icant role of the dysfunction/disruption of the DGC in 
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the molecular pathogenesis of muscular dystrophies is 
exemplified by our recent finding that the specific defi- 
ciency of the 50 kDa dystrophin-associated glycopro- 
tein (SODAG) alone causes a severe autosomal recessive 
DMD-like muscular dystrophy [ 151. These findings in- 
dicate that the efficacy of dystrophin gene therapy will 
depend not only on replacing dystrophin but also on 
restoring all of the DAPs in the sarcolemma of DMD 
patients. 
In the present study, we investigated the status of the 
DAPs in the skeletal muscle of mdx mice transgenic for 
the dystrophin gene, in order to know if the DAPs are 
restored properly in the sarcolemma when dystrophin 
is expressed. We performed the immunohistochemical 
and immunoblot analyses of these proteins in the large- 
caliber skeletal muscles of transgenic mdx mice, since 
the status of the DGC is well characterized in these 
muscles of mdx mice [ 131. The analysis of the phenotype 
of the transgenic mdx mice, including the histological 
study of various muscles, and the analysis of dystrophin 
expression in various tissues are reported in detail else- 
where (C.C. Lee et al., submitted for publication). 
2. MATERIALS AND METHODS 
A vector based on the muscle creatme kmase (MCK) promoter [16] 
was generated to drive the full-length dystrophm cDNA m transgenic 
mice (C.C. Lee et al., submitted for pubhcation). The MCK promoter 
construct (pCCLMCK-II) was constructed to contam the El and E2 
enhancers, and the 14 kb dystrophm cDNA was cloned mto thts vector 
to generate pCCLMCK-DMD Usmg the restrtctton enzymes Sull 
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Fig. 1. Immunohistochemical nalysis of dystrophin and the DAPs in the quadriceps muscle from a 15-week-old normal mouse, mdx mouse 
transgenic for the dystrophm gene and non-transgemc mdx sibling. Bar, 100 pm. 
and NotI, the MCK-DMD construct was excised from the plasmid 
sequence, gel electrophoresis separated and purified for microinjection 
into mouse embryos. Micromjection of FVB mouse embryos with 
MCK-DMD construct DNA generated a male transgenic mouse with 
this construct as determined by Southern blotting. Mdx transgenic 
mice were generated by breeding this male transgenic animal with mdx 
females to produce Fl transgenic and non-transgemc mdx male prog- 
eny. Sibling mdx male progeny of transgemc and non-transgenic phe- 
notype derived from this breeding scheme were analyzed in this study. 
Immunohistochemistry of the skeletal muscle (quadriceps and gas- 
trocnemius) was performed as described previously [8.13,14,17]. Serial 
transverse cryosections (7pm) were immunostamed with affimty-puri- 
fied rabbit polyclonal antibody against the last 10 ammo acids of the 
C-terminus of dystrophm, affinity-purified rabbit polyclonal antibody 
against the last 12 amino acids of the C-termmus of dystrophin-related 
protein and affimty-purified sheep polyclonal antibodies against the 
156 kDa dystroglycan (156DAG). the 59 kDa dystrophin-associated 
protein (59DAP). the SODAG, the 43 kDa dystroglycan (43DAG) 
and the 35 kDa dystrophm-associated glycoprotein (35DAG) 
[4.5,7,8,13,14.15.17]. 
Skeletal muscle membranes prepared from back and limb muscles 
and/or SDS extracts of skeletal muscle cryosections were separated on 
3312% SDS-PAGE and immunoblotted as described previously 
[13.15]. Immunoblots were stained with affinity-purified rabbit poly- 
clonal antibody against the last 10 ammo acids of the C-terminus of 
dystrophin. monoclonal antibody against the 156DAG (IIH6), and a 
cocktail of affinity-purified sheep polyclonal antibodies against the 
59DAP. SODAG. 43DAG and 35DAG as described previously [13,15]. 
For both immunohistochemical and immunoblot analyses, muscles 
from transgenic mdx mice were always compared with those from 
age-matched normal mice and non-transgenic mdx siblings simultane- 
ously. 
3. RESULTS AND DISCUSSION 
Southern analysis of the founder transgenic mouse 
has revealed the presence of a single copy transgene 
integration since a unique restriction enzyme band was 
observed with several enzymes on Southern blotting 
when probed with the 3’ MCK-DMD DNA fragment 
(not shown). The size of restriction enzyme bands from 
several of these enzymes was incompatible with a tail to 
tail in tandem integration. These results indicated that 
Table I 
Restoration of dystrophin and the DAPs in the skeletal muscle of mdx 
mice transgemc for the dystrophin gene. 
lmmunohistochemistry Immunoblotting 
Age 
(Weeks) 
3 
15 
30 
40 
45 
Muscle Fibers Positive for Dystrophin (%)b 
Dystrophin and DAPs (%) /156DAG (%)c 
25 15/40 
14 12135 
Not Determined I II37 
92 100/96 
47 44158 
“The prevalence of muscle fibers with positive staining for dystrophm 
and the DAPs. A total of 500 to 1,000 muscle fibers were counted for 
each mouse. 
’ Percentage of the amount of dystrophm compared with normal 
mouse (100%) as determined by the densitometry of the autoradi- 
ograms of the immunoblots of the SDS extracts of the skeletal muscle 
(3-week- and 15-week-old mice) or the skeletal muscle membranes 
(other mice). Dystrophin was not detected in the non-transgemc mdx 
siblings. 
’ Percentage of the amount of the 156DAG compared with normal 
mouse (100%) as determined by the densitometry of the autoradi- 
ograms of the immunoblots of the SDS extracts of the skeletal muscle 
(3-week- and 15-week-old mice) or the skeletal muscle membranes 
(other mice). Non-transgemc mdx siblings had the 156DAG of lo- 
20% of the normal level 
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Fig. 2. (A) Immunohistochemical analysis of dystrophin and the 
DAPs in the quadriceps muscle from a 40-week-old mdw mouse trans- 
genie for the dystrophin gene. Bar. 100 pm. 
the transgenic animal had a unique integration site with 
a single copy gene. 
Immunostaining for dystrophin expression in these 
Fl progeny has revealed significant variation of dystro- 
phin expression in different progeny derived from this 
one founder (Table I). Variation is also observed within 
different muscle fibers from different regions of the an- 
imal (Table I, Figs. 1 and 2a). It is highly possible that 
this variation in expression is inherent to the 
pCCLMCK-II construct since it may lack certain cis- 
acting elements for ubiquitous expression as demon- 
strated for the globin locus [18]. The variation of trans- 
gene expression in various progeny derived from a 
single founder may be due to the outbred genetic back- 
ground of the progeny from breeding FVB founder 
mouse with C.57 black mdx female mouse. Variation in 
progeny genetic background from such a breeding strat- 
egy may contribute to the differences observed in trans- 
gene expression since a strain-specific modifier [19] has 
been described to regulate transgene expression. 
In order to investigate the status of the components 
of the DGC in the skeletal muscle of mdx mice trans- 
genie for the dystrophin gene, we performed the immu- 
nohistochemical analysis of dystrophin and the DAPs. 
As controls, we investigated both age-matched normal 
mice and non-transgenic mdx siblings simultaneously. 
As described previously [13], dystrophin and all of the 
DAPs were co-localized to the sarcolemma in normal 
mice. while dystrophin was absent and all of the DAPs 
were drastically diminished in the sarcolemma of non- 
transgenic mdx siblings (Fig. 1). In order to show the 
specificity of the restoration of the DAPs in mdx mice 
CB 
Anti- 
DYS 
llH6 
(Anti-1 56DAG) 
Anti- 
DAPs 
224- -c- 
. 
109 - 
72 - 
46 - 
29 - 
123 123 123 123 
1 = Normal Mouse 
2 = Transgenic Mdx Mouse 
3 = Non-Transgenlc Mdx Mouse 
Fig. 2. (B) Immunoblot analysis of dystrophin and the DAPs m the 
skeletal muscle membranes from 40-week-old normal mouse (lane 1). 
mdx mouse transgenic for the dystrophm gene (lane 2) and non- 
transgenic mdx sibling (lane 3). One hundred and 400 pg of mem- 
branes were loaded for Coomassie-blue staining of the gel and im- 
munoblottmg, respectively. Molecular weight standards (x lo-‘) are 
shown on the left. 
transgenic for the dystrophin gene, we investigated 
transgenic mice expressing dystrophin at various levels 
(range 14-92%, Table 1). As shown in Figs. 1 and 2a. 
muscle fibers expressing dystrophin along the sar- 
colemma were found in transgenic mice. Examination 
of the serial transverse cryosections revealed that all of 
the DAPs were not only restored but also co-distributed 
with dystrophin in the sarcolemma of dystrophin-posi- 
tive fibers (Figs. 1 and 2a). Dystrophin-related protein 
(DRP), an autosomal homologue of dystrophin [ 17,201, 
did not co-localize with dystrophin and the DAPs in 
these fibers (not shown). 
Restoration of dystrophin and the DAPs in the skel- 
etal muscle of transgenic mdx mice was confirmed by 
the immunoblot analysis of the skeletal muscle mem- 
branes (Fig. 2b) and/or the SDS extracts of the skeletal 
muscle (not shown) (Table I). While dystrophin was 
absent and the DAPs were drastically reduced in the 
skeletal muscle of non-transgenic mdx siblings as re- 
ported previously [13], dystrophin and the DAPs were 
restored to various degrees in the skeletal muscle of 
transgenic mdx mice (Fig. 2b, Table I). The level of 
restoration of these proteins on immunoblot analysis 
showed a good correlation with that on immunohisto- 
chemistry (Fig. 2. Table I). 
In mdx mice, a very small percentage of muscle fibers 
(less than 1 to 2%) are reported to show dystrophin 
staining along the sarcolemma [21]. Somatic reversion 
or suppression of mdx mutation in vivo was proposed 
as an explanation for these rare fibers [21]. However. a 
possibility that the present findings represent this phe- 
nomenon rather than the effect of transfection of the 
dystrophin gene is negated based on the following: (1) 
in non-transgenic mdx siblings, dystrophin-positive 
muscle fibers were quite rare (less than 1%) on immu- 
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nohistochemistry and dystrophin was not detected on 
immunoblot analysis; (2) the prevalence of dystrophin- 
positive muscle fibers in transgenic mdx mice was high 
(Table I). 
Thus. we have demonstrated the co-restoration of 
dystrophin and all of the DAPs in the sarcolemma of 
mdx mice transfected with the dystrophin gene. Most 
importantly, dystroglycan ( 156DAG143DAG) which 
provides a linkage to the extracellular matrix and the 
SODAG whose deficiency alone causes severe childhood 
autosomal recessive muscular dystrophy with DMD- 
like phenotype (SCARMD) were restored together with 
dystrophin, 59DAP and 35DAG. 
Previously, we have demonstrated that the absence of 
dystrophin leads to the deficiency in all of the other 
components of the DGC in DMD and mdx skeletal 
muscle. In SCARMD, the deficiency of the SODAG is 
presumed to lead to the secondary reduction of the 
35DAG. There are a few genetic diseases in which a 
deficiency of one component in a protein complex can 
result in the loss of the other components. For instance, 
hereditary elliptocytosis. characterized by a defect in 
spectrin, is also associated with deficiencies in protein- 
4.1 and minor sialoglycoproteins [22]. Skeletal muscle 
phosphorylase kinase deficiency is characterized by the 
combined loss of all four subunits of this enzyme [23]. 
However, the present study is the first to demonstrate 
that transfer of the causative gene restores not only its 
protein product but also the other components of the 
complex. 
Recently, we have identified a single gene encoding 
both the 156DAG and 43DAG. and have demonstrated 
that the level of expression of dystroglycan (156DAG/ 
43DAG) mRNA is indistinguishable between normal 
and mdx mice [7]. These findings suggested that these 
DAPs were produced at the normal level, but were not 
properly assembled and/or integrated into the sar- 
colemma or were degraded, in the absence of dystrophin 
in mdx mice [7]. Thus, it is most likely that dystrophin 
facilitates the assembly of the DAPs into the sar- 
colemma and/or stabilizes them in the sarcolemma in 
transgenic mdx mice. 
Currently, research is in progress on dystrophin gene 
therapy. However, recent discoveries on the role of the 
DAPs in the molecular pathogenesis of DMD raise seri- 
ous questions concerning the efficacy of dystrophin 
gene therapy [24-271. In order for this therapy to be 
successful, the entire DGC will have to be restored in 
DMD muscle. Thus, the goal of dystrophin gene ther- 
apy must be the replacement of dystrophin and the 
restoration and stabilization of the DAPs, in order to 
restore the normal linkage between the subsarcolemmal 
cytoskeleton and the extracellular matrix. The observa- 
tion of dystrophin along the sarcolemma after such 
therapies cannot indicate the restoration of all of the 
DAPs in the sarcolemma, because dystrophin could be 
properly localized to the sarcolemmal region due to its 
association with other subsarcolemmal cytoskeletal 
components such as g-actin even when it is not associ- 
ated with the DAPs. Indeed we have demonstrated re- 
cently that dystrophin is properly localized to the 
SCARMD sarcolemma in which the deficiency of the 
SODAG causes a reduction of the 35DAG [15]. We have 
also found that truncated dystrophin lacking the C- 
terminal domains is properly localized to the sar- 
colemma even though it is not associated with the DAPs 
(K. Matsumura. personal communication) and that 
dystrophin is localized to the sarcolemma in 
Fukuyama-type congenital muscular dystrophy in 
which the DAPs are reduced in the sarcolemma [28]. 
Thus, our results demonstrating the co-restoration of 
dystrophin and all of the DAPs in the sarcolemma of 
a substantial percentage of muscle fibers in transgenic 
mdx mice answer this crucial question and indicate that 
dystrophin gene therapy could be effective. 
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